Lantern Pharma
Princeton, Texas, United States
Dr. Aditya Kulkarni is a Senior Research Scientist and Program Manager at Lantern Pharma. He is an oncology precision medicine professional and inventor combining over 10 years of research experience with a vision to integrate science and business to direct drugs from the bench to the bedside. He has been a key contributor to translational research functions and capabilities. He has been instrumental in defining clinical development strategies for small molecules in adult and pediatric solid tumors and rare cancers. He welcomes challenges, embraces scientific rigor, and co-creates vision in an effort to move the organizational portfolio forward in a collaborative environment. He is the primary inventor and author on 10+ patents and patent applications on candidate drugs and their response associations with biomarkers and cancer indications. Dr. Kulkarni is a collaborator experienced in working with academic and industrial research partners such as the National Cancer Institute (NCI), Fox Chase Cancer Center, Johns Hopkins University, Charles River Laboratories, Champions Oncology etc. to drive results in a time-efficient and innovative manner. A scientist familiar with the laboratory and the board room, Dr. Kulkarni is a co-author on 10+ papers in academic journals. He is skilled at needs identification, hypothesis generation, study design, protocol implementation and opportunity assessment related to oncology agents, indications, patients, and markets, and has knowledge of budgeting, timelines, business contracts, and intellectual property frameworks. He is adept at working with cross-functional teams including management, research, clinical development, machine learning and medical affairs experts to identify key gaps in scientific and clinical knowledge and to synthesize research plans to generate or leverage the appropriate data, either internally or via collaborations. Dr. Kulkarni completed his postdoctoral training at UT Southwestern Medical Center in Dallas. and holds a Ph.D. in Biochemistry and Molecular Biology from Baylor College of Medicine in Houston.
